Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)
Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach
The purpose of this study is to determine of once identified to the subjects infected with human immunodeficiency virus (positive VIH), to diagnose latent Tuberculosis, and to treat her with isoniazid for six months, measuring the production of Interferon range pre and posttreatment, to evaluate this way the result of the treatment on the immune response
A descriptive analysis of the data will be made. Means and standard deviations for continuous data frequencies for categorical data will be performed. Wilcoxon test Mann-Whitney U test Chi square will be used for frequency analysis of responders Data Analysis and Statistical Software(STATA).
Isoniazid, 10 mg/Kg/day, no more than 300 mg/day, for six months
Inclusion Criteria: Accept to participate. Informed consent. Human Immunodeficiency Virus positive test, documented by Western Blot Have not received treatment for latent tuberculosis Have not been diagnosed pulmonary tuberculosis (Tbp) Normal two chest X-rays, Postern-anterior and left lateral. Exclusion Criteria: Active tuberculosis Previous diagnosis of tuberculosis Antecedent of treatment for active o latent tuberculosis Contact with TB patient harboring Multidrug resistance or isoniazid resistant isolates of Mycobacterium tuberculosis. Abnormal liver enzyme levels Hemoglobin below 8 gr/dl Allergy or intolerance to isoniazid Peripheral neuropathy Ingestion of drugs interacting with isoniazid